Drugs / BIIB021
BIIB021
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01017198 | Nov 2009 → Aug 2010 | cancer | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT00618735 | Feb 2008 → Jul 2010 | cancer | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT00412412 | Dec 2007 → Apr 2011 | breast cancer | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT00345189 | Feb 2006 → Jul 2008 | lymphoma | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT00344786 | Feb 2006 → Jul 2008 | B-cell chronic lymphocytic leukemia | Biogen | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01004081 | Nov 2009 → Oct 2011 | breast cancer | Biogen | Completed | No outcome recorded |
| Phase 2 | NCT00618319 | Feb 2008 → Apr 2010 | gastrointestinal stromal tumor | Biogen | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB021 | “CNF2024 (BIIB021)” NCT00344786 ↗ |
| Known as | CF1983 | “The active pharmaceutical ingredient of CNF2024, CF1983 mesylate, is a synthetic, new chemical entity designed to inhibit Hsp90.” NCT00345189 ↗ |
| Known as | CF1983 mesylate | “The active pharmaceutical ingredient of CNF2024, CF1983 mesylate, is a synthetic, new chemical entity designed to inhibit Hsp90.” NCT00345189 ↗ |
| Known as | CNF2024 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00412412 ↗ |
| Known as | CPD 20 | ChEMBL registry synonym — accepted as the source's own label CHEMBL467399 ↗ |
| Action | Inhibit | “designed to inhibit Hsp90” NCT00345189 ↗ |
| Modality | Small molecule | “CF1983 mesylate, is a synthetic, new chemical entity” NCT00345189 ↗ |
| Route | Oral | “CNF2024 Administered Orally” NCT00344786 ↗ |